Related references
Note: Only part of the references are listed.Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection?
Roger Y. Dodd et al.
TRANSFUSION (2018)
Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing
Nico Lelie et al.
TRANSFUSION (2017)
Fifteen years of Nucleic Acid Testing in France: Results and lessons
S. Laperche et al.
TRANSFUSION CLINIQUE ET BIOLOGIQUE (2017)
Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe
Nyashadzaishe Mafirakureva et al.
TRANSFUSION (2016)
Prevalence of antibody to Hepatitis B core antigen and Hepatitis B virus DNA in HBsAg negative healthy blood donors
Gharib Karimi et al.
VIROLOGY JOURNAL (2016)
Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection
Philip Kiely et al.
TRANSFUSION (2014)
HIV, HCV, HBV and syphilis surveillance among blood donors in Germany 2008-2010
R. Offergeld et al.
BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ (2012)
Cost-effectiveness of additional blood screening tests in the Netherlands
Barbara A. Borkent-Raven et al.
TRANSFUSION (2012)
International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009
W. K. Roth et al.
VOX SANGUINIS (2012)
Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels
Azzedine Assal et al.
TRANSFUSION (2009)
Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions
C. Micha Nuebling et al.
TRANSFUSION (2009)
The harmonization of the regulation of blood products: a European perspective
R. Seitz et al.
VOX SANGUINIS (2008)
Assessing the impact of HBV NAT on window period reduction and residual risk
Steven H. Kleinman et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000
J Pillonel et al.
TRANSFUSION (2002)